Certara Appoints Eran Broshy as New Independent Board Member
July 13 2022 - 8:00AM
Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,
today announced the appointment of Eran Broshy to its Board of
Directors, effective July 11, 2022. His appointment brings the
company’s board of directors to ten members.
“Eran has a proven track record taking high-growth healthcare
businesses to the next level and delivering superior results,” said
William Feehery, Ph.D., CEO of Certara. “Certara is excited to have
someone of his caliber and experience join the board. I look
forward to Eran’s contribution in guiding us as we grow our impact
by informing critical decisions in drug development with
biosimulation, technology and analytics.”
Mr. Broshy is an accomplished veteran board director and private
equity operating executive with more than 35 years of experience
working broadly across healthcare. Mr. Broshy also served for over
a decade as chief executive officer and chairman of inVentiv Health
(now part of Syneos Health), and under his leadership the company
transformed into the leading global provider of clinical and
commercialization services. Earlier in his career, he spent 15
years at The Boston Consulting Group (BCG), where he was a managing
director and partner responsible for the firm’s healthcare practice
across the Americas. Mr. Broshy currently serves on the boards of
Theravance Biopharma (Nasdaq: TBPH), a respiratory-focused biotech
company, and Thirty Madison, a digital healthcare company. He is
also a member of the Corporation of the Massachusetts Institute of
Technology.
“I am pleased to join the board of a dynamic organization that
is transforming the drug development process and improving patient
outcomes with its unique technologies and expert team,” said Mr.
Broshy. “I am looking forward to making a valuable contribution to
Certara and helping it achieve its mission of accelerating
medicines to patients.”
About Certara Certara accelerates medicines
using proprietary biosimulation software, technology and services
to transform traditional drug discovery and development. Its
clients include more than 2,000 biopharmaceutical companies,
academic institutions, and regulatory agencies across 62
countries.Certara ContactJieun W.
Choejieun.choe@certara.com
Investor Relations ContactDavid
Deuchlerir@certara.com
Media Contact:Ariane LovellFinn
Partnersariane.lovell@finnpartners.com
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Sep 2023 to Sep 2024